Aristeia Capital L.L.C. Invests $3.40 Million in LivaNova PLC (NASDAQ:LIVN)

Aristeia Capital L.L.C. purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 73,300 shares of the company's stock, valued at approximately $3,395,000. Aristeia Capital L.L.C. owned approximately 0.13% of LivaNova at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Freestone Grove Partners LP bought a new position in LivaNova in the 4th quarter valued at $23,102,000. Artisan Partners Limited Partnership purchased a new stake in shares of LivaNova in the 4th quarter worth about $21,340,000. The Manufacturers Life Insurance Company grew its stake in LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after purchasing an additional 339,139 shares during the period. AQR Capital Management LLC lifted its holdings in shares of LivaNova by 79.3% during the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock valued at $34,214,000 after purchasing an additional 328,313 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after purchasing an additional 265,291 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Up 2.4 %

NASDAQ:LIVN traded up $1.03 on Thursday, reaching $44.53. The stock had a trading volume of 615,602 shares, compared to its average volume of 630,504. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average of $37.79 and a 200 day moving average of $45.33. The stock has a market cap of $2.43 billion, a P/E ratio of 106.02 and a beta of 0.84. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $63.57.

Analysts Set New Price Targets

Several research firms have weighed in on LIVN. Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday. Barclays lowered their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday. Stifel Nicolaus reduced their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.